Ouyi

Quick links to important sections

Medically reviewed

Laura Arias

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Ouyi

Property Description
Active ingredient Cefadroxil (Cefadroxil monohydrate)
Form Oral suspension, capsules, tablets
Pharmacological class Antibiotic, First-Generation Cephalosporin
Common purpose To eliminate susceptible bacterial infections
Origin Semi-synthetic (chemically derived)

What Type of Medicine is Ouyi (Cefadroxil)?

Ouyi is the trade name for a medicine containing the active ingredient Cefadroxil, which is classified as an antibiotic used to combat infections caused by bacteria. More precisely, Cefadroxil belongs to the cephalosporin family of antimicrobial agents and is categorized as a first-generation agent. This specific classification is clinically recognized for targeting common gram-positive bacteria, a key factor in its use for specific infection types.

This classification establishes Cefadroxil as a semi-synthetic compound; its core structure is derived from a natural origin but requires laboratory modification for therapeutic use. The drug is manufactured as a single-ingredient product, distinguishing it from combination drugs, and is available globally under various brand names, all sharing the same therapeutic profile.


The General Purpose and Composition of Ouyi

The general purpose of Ouyi is to function as a bactericidal agent that effectively eliminates harmful bacteria causing systemic infections. Its mechanism enables it to act as a broad-spectrum agent, targeting a wide range of common bacterial pathogens, which assists the body in recovering from the resulting disease state. Cefadroxil is associated with success in resolving various infections, including those affecting the skin and soft tissues. This efficacy supports its role in clearing established bacterial colonization.

For patient administration, Ouyi is formulated for oral administration and is available in multiple convenient dosage forms, including capsules, tablets, and a powder that is reconstituted into an oral suspension. The liquid suspension form is often highlighted for its suitability and ease of administration to pediatric patients. The availability of both solid and liquid forms ensures accessibility for various patient groups, while its core composition remains centered on the efficacy of the Cefadroxil active ingredient.

What side effects are possible with Ouyi?

Possible Side Effects and Safety Information

The official safety profile for Ouyi (Cefadroxil) documents potential adverse reactions categorized by frequency and system-organ class, as required by regulatory authorities. The most frequently observed reactions affect the Gastrointestinal disorders and Skin and subcutaneous tissue disorders categories.


Documented Adverse Reactions

The following is based on the frequency framework used in official regulatory labeling:

  • Common (typically ge 1/100 to <1/10): Gastrointestinal disturbances such as diarrhea, nausea, and vomiting, along with rash and pruritus (itching).
  • Uncommon (typically ge 1/1,000 to <1/100): Overgrowth of non-susceptible organisms, including vaginal mycoses or oral thrush.
  • Rare (typically ge 1/10,000 to <1/1,000): Reports include drug fever, angioedema, and specific changes in blood counts like agranulocytosis.

Serious Adverse Reactions and Safety Constraints

The regulatory safety profile highlights several reactions that are rare but clinically significant. Allergic reactions pose a primary constraint, with anaphylactic shock listed as a rare, potentially life-threatening event. A significant risk documented for broad-spectrum antibiotics is Pseudomembranous Colitis (Clostridioides difficile-associated diarrhea), which can occur during or up to two months after treatment completion. Severe Cutaneous Adverse Reactions (SCAR), such as Stevens-Johnson syndrome, are also officially listed as rare risks.

Safety statements also mandate caution regarding cross-hypersensitivity in patients with a known severe allergy to penicillins. Additionally, the medicine's primary elimination route through the kidneys necessitates careful consideration in patients with markedly impaired renal function.

Overdose and Emergency Response

Overdose and when to seek help

The official regulatory profile for Ouyi (Cefadroxil) overexposure details specific clinical manifestations and mandates immediate emergency action.

Overdose Scope

Property Official Regulatory Statement
Documented overdose presentations: Overexposure may lead to gastrointestinal effects such as nausea, vomiting, and diarrhea.
Physiological systems affected: Gastrointestinal system and Central Nervous System (CNS).
Dose-related or exposure-related factors: Manifestations are typically associated with massive overexposure.
Population-specific overdose notes: Patients with impaired renal function face an increased risk of severe CNS toxicity, including seizures, due to drug accumulation.
Emergency-response statements: Seek immediate medical attention for any suspected overdose. Emergency services should be contacted if the victim collapses or experiences a seizure.

Overdose Classifications (High-Level)

Classification Aspect Official Regulatory Statement
Severity classification: Ranges from non-life-threatening digestive symptoms to serious, high-concentration-related neurological events.
Overdose-context constraints: No specific antidote is known. Management is defined as symptomatic and supportive.

Resulting Overdose Structure

Official overdose statements:

  • Massive overexposure can result in severe CNS findings, including seizures and neuromuscular excitability.
  • Treatment is limited to symptomatic and supportive measures.
  • Management procedures described in labeling include gastric lavage, activated charcoal, and the potential use of hemodialysis for drug removal.

The regulatory profile explicitly defines the risks of Cefadroxil overexposure through these documented manifestations and mandates the immediate involvement of emergency medical care when overdosage is suspected, particularly in scenarios involving severe neurological symptoms.

Therapeutic Uses of Ouyi

What Ouyi Treats: Main Uses and Benefits

Ouyi (Cefadroxil) is commonly used to help address bacterial infections, supporting symptomatic relief across several key clinical domains characterized by acute or episodic changes and systemic or localized discomfort. In clinical use, it is generally applied to infections caused by susceptible strains of designated organisms.

Ouyi is commonly used for managing conditions characterized by periods of heightened symptoms, including infections linked to the skin and soft tissues (such as impetigo), uncomplicated urinary tract infections (UTIs), and acute pharyngitis or tonsillitis. In these situations, the therapy helps ease symptoms that create noticeable physiological strain, such as localized pain, redness, swelling, and painful urination.

“This agent is relevant in contexts involving heightened systemic burden where short-term symptomatic assistance is needed.”

Supporting Symptomatic Relief

The application of this agent assists with addressing the bacterial cause, which generally contributes to improved day-to-day comfort and supports functional stability during the illness. Ouyi helps address symptom clusters that may become intense or disruptive, such as the acute pain in the throat or the localized inflammation and tenderness found in bacterial skin infections. Beyond addressing active disease, it is considered relevant in contexts involving heightened systemic burden, such as when supportive symptomatic management is appropriate for short-term prophylaxis during certain procedures in at-risk patients.


Quick Fact: Relief for Pain and Inflammation

Ouyi helps address symptom clusters that may become intense or disruptive, such as the acute pain in the throat or the localized inflammation and tenderness found in bacterial skin infections.

Regulatory References

  1. NIH DailyMed drug information

Eligibility and Restrictions for Use

Who Can and Cannot Use Ouyi?

Eligibility for Ouyi (Cefadroxil) is defined by official regulatory criteria, primarily based on patient history, kidney function, and age-related factors.


Eligibility Status Population/Condition
Contraindicated (Must Not Use) Patients with known hypersensitivity or severe allergic reaction to the cephalosporin class of antibiotics.
Conditional Use (Use with Caution) Patients with markedly impaired renal function (Creatinine clearance less than 50 mL/min/1.73 m^2).
Individuals with a history of gastrointestinal disease, particularly colitis.

Age-Related Eligibility

Ouyi is generally approved for use in adults and pediatric patients. Specific restrictions apply to children: for example, the capsule form is not recommended for infants and children under six years of age. Geriatric patients are generally eligible, but caution is advised due to the higher likelihood of age-related decline in kidney function, which can affect the drug’s clearance.

Pregnancy and Lactation

The use of Ouyi during pregnancy is not uniformly established as safe across all regulatory regions. Since the medicine is excreted into human breast milk, caution should be exercised when administered to a nursing mother.

What should I know about interactions with other medicines?

Ouyi Interactions with other medicines and products

Official regulatory documents define several important interaction patterns for Ouyi (Cefadroxil) related to drug concentration, toxicity, and efficacy of co-administered products.

Interacting Product Category Official Interaction Pattern
Transporter Inhibitors Probenecid increases the plasma concentration of Cefadroxil by inhibiting its renal clearance (tubular secretion).
Nephrotoxic Agents Co-administration with Aminoglycosides or High-dose Loop Diuretics may potentiate the risk of nephrotoxicity.
Anticoagulants The use with Vitamin K Antagonists (e.g., Warfarin) may enhance the anticoagulant effect, necessitating monitoring for haemorrhagic complications.
Hormonal Contraceptives May diminish the effectiveness of Estrogen-containing Oral Contraceptives through alteration of the intestinal flora.
Bacteriostatic Antibiotics Co-administration is generally prohibited due to the possibility of an antagonistic effect on antimicrobial action.
Live Vaccines Typhoid Vaccine (live) and Cholera Vaccine (live) require mandatory timing separation. The antibacterial action of Cefadroxil may diminish the vaccine's therapeutic effect.
Laboratory Assays Treatment is associated with potential false-positive results for specific Urinary Sugar Reduction Tests and may cause a Positive Direct Coombs' Test.

Mechanism of Action

Ouyi (Cefadroxil) functions as a bactericidal agent by interrupting the processes essential for the structural integrity of susceptible bacterial cells. Its mechanism is highly specific, targeting the Penicillin-Binding Proteins (PBPs), which are transpeptidase enzymes crucial for cell wall assembly. Ouyi acts as an irreversible inhibitor, forming a stable covalent bond that permanently stops the PBPs from performing their function. This inhibition prevents the peptidoglycan chains from cross-linking, resulting in the construction of a structurally defective and osmotically weak bacterial cell wall. The subsequent inability of the cell to withstand its internal pressure leads to its rapid rupture, known as lysis, and ultimately, the systemic elimination of the actively dividing pathogen load. The mechanism is constrained by bacterial strains that produce beta-lactamase enzymes, which chemically destroy the Cefadroxil molecule before it can bind to the PBPs, neutralizing the inhibitory action.

Dosage and Administration Information

How to Use Ouyi

Ouyi (Cefadroxil) is an oral antibiotic and its usage is strictly defined by clinical guidelines concerning administration route, dosing, frequency, and duration. The medicine is available as capsules, tablets, and an oral suspension.

Administration and Dosing

The standard adult dosing schedule for Ouyi typically involves a total daily dose ranging from 1 gram (g) to 2 g, which is administered either as a single dose once per day or in two equally divided doses every 12 hours.

Population Group Labeled Dosing Principle
Adults Daily dose of 1 g to 2 g; maximum dose up to 4 g/day is cited in official clinical documentation.
Pediatric Patients Dose is determined by body weight, commonly 30 mg/kg/day.
Renal Impairment Dosage requires mandatory adjustment based on the patient's measured Creatinine Clearance (CrCl) rate to avoid drug accumulation.

Contextual Use Instructions

Ouyi may be taken with or without food; the option to take it with food is available to help reduce potential gastrointestinal discomfort. The powder for oral suspension must be reconstituted with water prior to use, and the liquid must be shaken well before each dose is measured.

Treatment Duration

The full prescribed course of therapy must be completed. For infections caused by Group A beta-hemolytic streptococci (e.g., pharyngitis), a minimum treatment duration of 10 days is required. For other infections, administration generally continues for at least two to three days after the acute symptoms have resolved. If a dose is missed, patients should not take two doses simultaneously to compensate.

Recent Clinical Evidence

Ouyi: Recent Clinical Evidence

CSPC Ouyi Pharmaceutical Co., Ltd. is the sponsor for multiple ongoing and completed clinical trials investigating various drug candidates, focusing on different therapeutic areas, including metabolic disorders, oncology, and central nervous system (CNS) conditions.

Approved Products and Indications

One of the company's notable approved products is levamlodipine (CONJUPRI), which was approved by the U.S. FDA in 2019. This drug is a calcium channel blocker indicated for the treatment of hypertension (high blood pressure) in adults and pediatric patients aged 6 years and older. Data from clinical and non-clinical studies supported its approval for blood pressure lowering, which is associated with a reduced risk of cardiovascular events.

Current Research Activities

Clinical development programs are actively investigating other compounds. Examples of ongoing Phase 3 trials include:

  • A randomized, double-blind, placebo-controlled trial evaluating a sustained-release combination of dextromethorphan and bupropion in adult patients with Major Depressive Disorder (MDD). This trial is designed to assess efficacy and safety endpoints using standardized rating scales like the Montgomery-Åsberg Depression Rating Scale (MADRS).
  • A Phase 3 multicenter trial assessing a combination therapy of prusogliptin, dapagliflozin, and metformin in subjects with Type 2 Diabetes who have insufficient glycemic control on metformin alone. This research aims to evaluate the safety and effectiveness of the triple combination approach.
  • A separate Phase 3 study is underway to evaluate an extended-release formulation of pregabalin for the management of neuropathic pain associated with diabetic peripheral neuropathy.

These studies utilize standard randomized, controlled designs to compare the study drug's performance against a placebo or an active comparator, generating the evidence required for regulatory submission and clinical assessment.

Frequently Asked Questions (FAQ)

Common questions about Ouyi (FAQ)


Q: How long does it typically take for Ouyi to start working?

A: Clinical studies indicate that the active ingredient is typically rapidly absorbed, with peak concentrations in the bloodstream generally reached within approximately one to two hours after taking the medication. Many patients may start to notice improvement during the first few days of treatment, although individual response times can vary. It is important to complete the full prescribed course.


Q: Can Ouyi be taken with common over-the-counter pain relievers?

A: Official regulatory documents caution that Ouyi may have a potential for interaction with certain medications, including some Non-Steroidal Anti-Inflammatory Drugs (NSAIDs). This interaction may affect the drug's concentration in the body or increase the risk of specific side effects. Regulatory guidelines emphasize the importance of informing healthcare providers about all medications, including over-the-counter products, when starting treatment.


Q: What happens if you stop taking Ouyi suddenly?

A: According to the official product information, stopping Ouyi too soon or skipping doses may decrease the effectiveness of the treatment. Crucially, this practice may also increase the risk of the infection-causing bacteria developing resistance to antibiotics, making future infections harder to treat. It is essential to continue Ouyi for the entire time prescribed.


Q: Will Ouyi affect my ability to drive or operate machinery?

A: Regulatory documents do not specifically advise against driving or operating machinery. However, rare side effects have been reported that affect the central nervous system, such as dizziness or nervousness. Patients who experience side effects such as dizziness or nervousness should be cautious when performing tasks that require full attention.


Q: How long does the effect of one dose of Ouyi last?

A: The average plasma half-life (the time required for half of the drug to be eliminated) is approximately 1.5 hours in individuals with normal kidney function. Official data indicates that over 90% of the drug is naturally excreted within 24 hours.


Q: Do older adults react differently to Ouyi than younger adults?

A: Official information notes that Ouyi is mainly processed and removed from the body by the kidneys. Because older adults are more likely to have some decreased kidney function, regulatory caution is advised, and dosage adjustment, as determined by a healthcare provider, may be necessary.


Q: Is Ouyi a long-term treatment or just for a short time?

A: Ouyi is designed to be a short-term treatment to eliminate a bacterial infection. Treatment involves completing the full course of therapy prescribed by a healthcare professional; it is not typically intended for long-term use.


Q: Are there any documented cases of Ouyi losing effectiveness over time?

A: While the drug is effective, regulatory warnings highlight that incomplete treatment or misuse can lead to the development of drug-resistant bacteria. If bacteria become resistant, the medication will no longer be effective against that particular strain.


Q: Is Ouyi safe for breastfeeding mothers?

A: According to the official prescribing information, the active ingredient in Ouyi, Cefadroxil, is excreted into human breast milk. Due to this, official guidance states that caution is warranted when the medication is administered to a woman who is nursing.


Q: Is Ouyi ever used in combination with other prescription drugs?

A: Yes, Ouyi is sometimes used as an adjunctive or preventative measure. The drug is indicated for the prevention of bacterial endocarditis (a heart infection) in specific patients who are undergoing certain dental or upper respiratory tract procedures.


Q: Does Ouyi affect laboratory test results?

A: Yes, regulatory documents indicate that treatment with Ouyi can cause false-positive results in certain lab tests. These include the Direct Coombs' Test and specific methods used for determining urinary sugar (glucose) levels.


Q: Are there any dietary restrictions associated with Ouyi?

A: Official regulatory prescribing information states that Ouyi can be taken with or without food. Taking it with food is an acceptable option that may help to reduce the occurrence of common gastrointestinal side effects like nausea.


Q: What are the storage instructions for Ouyi?

A: Storage instructions vary by form. Tablets and capsules should be stored at controlled room temperature, typically 20 to 25 C. The liquid suspension (reconstituted powder) typically requires refrigeration and generally should be discarded after a specific period, such as 14 days, unless otherwise specified on the label.


Q: How should Ouyi be disposed of if expired?

A: Ouyi is not classified as a drug that requires specific hazardous disposal. Official guidance recommends disposing of unused or expired medicine by taking it to an authorized drug take-back program or by following the general practice of mixing it with an unappealing substance, like dirt, before placing it in the trash.


Q: What are the less common but possible side effects of Ouyi?

A: Official safety documents list less common side effects such as the overgrowth of non-susceptible organisms, which can lead to conditions like oral thrush or vaginal mycoses. Rare but serious reactions, such as drug fever or angioedema, are also documented.


Q: Is Ouyi used to prevent conditions or treat existing ones?

A: Ouyi has both roles according to official documents. It is primarily indicated to treat existing infections caused by susceptible bacteria, but it is also approved to prevent bacterial endocarditis in specific patient cases before certain procedures.


Q: Are there different forms of Ouyi (e.g., tablet, liquid)?

A: Yes, the drug is available in multiple formulations to suit different patient needs. These include capsules, tables, and a powder for oral suspension (the liquid form), which is often used for pediatric patients.


Q: What should I tell my dentist before a procedure if I'm taking Ouyi?

A: It is important to inform your dentist that you are taking Ouyi, particularly if you have a history of certain heart conditions or are allergic to penicillin. The drug is sometimes used to prevent heart valve infection in these patients when they undergo dental or respiratory procedures.


Q: Has Ouyi been tested in pediatric populations?

A: Yes, Ouyi is approved for use in pediatric patients. Dosage instructions for children are calculated based on factors such as body weight. Official guidance notes that some forms, like the capsule, are typically not recommended for infants and children under six years of age.


Q: Can Ouyi make existing conditions worse?

A: Regulatory warnings state that patients with a history of gastrointestinal disease, particularly colitis, should use Ouyi with caution. This is because broad-spectrum antibiotics carry a documented risk of causing a severe form of diarrhea known as Pseudomembranous Colitis.

How should Ouyi be stored and disposed of?

How to Store and Dispose of Ouyi (Official Regulatory Information)

This information reflects the mandatory requirements for storing and handling Ouyi (levamlodipine) as defined in official regulatory labeling.


Storage Requirements

Condition Requirement (Official Statement)
Temperature Store at 20 to 25 C (68 to 77 F) Controlled Room Temperature.
Excursions Excursions permitted from 15 to 30 C (59 to 86 F).
Protection Protect from light. Dispense in light-resistant containers.

Disposal Requirements

Official labeling typically directs users to follow established government-sanctioned protocols for safe disposal of unused or expired medicine. This prevents accidental exposure and environmental contamination. No special hazardous-waste classification is typically specified in the patient-facing storage instructions.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Ouyi found in:

A-Z Index: